Detection of residual neuroblastoma cells in bone marrow: Comparison of flow cytometry with immunocytochemistry
Open Access
- 26 July 2004
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 61B (1) , 9-19
- https://doi.org/10.1002/cyto.b.20019
Abstract
BACKGROUND Because the cytomorphologic examination of bone marrow (BM) aspirates appears not sensitive enough to detect residual neuroblastoma cells, two four‐color flow cytometric assays using different combinations of CD9, CD81, CD56, CD45, and anti‐GD2 were evaluated. METHODS The sensitivity of the flow cytometric assays was assessed by spiking experiments in normal peripheral blood samples. Twenty‐eight BM samples, 12 biopsies, and 3 peripheral blood stem cell (PBSC) preparations from 22 patients with neuroblastoma were analyzed. The results were compared with those of an anti‐GD2 immunocytochemical reference assay. RESULTS Flow cytometric and immunocytochemical analyses showed residual neuroblastoma cells in four BM samples. One PBSC preparation and 20 BM samples were negative for both assays. Four BM and two PBSC samples scored positive for the immunocytochemical assay but were negative for the flow cytometric tests. This was due to the limited number of cells that were flow cytometrically analyzed. A strong correlation between the flow cytometric and immunocytochemical tests was found (χ2 = 6.4, P = 0.011). CONCLUSIONS When an equal amount of cells is analyzed, the sensitivity of the flow cytometric assays is to be about 10 times lower than that of the immunocytochemical test. However, the flow cytometric assays can be used to screen for residual cells in clinical samples with a sensitivity of one neuroblastoma cell in 104 to 105 normal mononuclear cells. Flow cytometry is simple, quick, and cost effective compared with immunocytochemistry. In addition, the flow cytometric assays can be used to screen for residual neuroblastoma cells in case of a GD2‐negative primary tumor. Therefore we recommend flow cytometry for the detection of residual neuroblastoma cells.Keywords
Funding Information
- Flemish Institute for the Promotion of Scientific Technological Research in Industry
This publication has 29 references indexed in Scilit:
- Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase‐polymerase chain reactionCancer, 2003
- Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patientsCytometry, 2002
- Advances in the immunological monitoring of childhood acute lymphoblastic leukaemiaBest Practice & Research Clinical Haematology, 2002
- Unequivocal identification of disseminated tumor cells in the bone marrow by combining immunological and genetic approaches – functional and prognastic informationLeukemia, 2001
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusionsEuropean Journal Of Cancer, 1997
- Prognostic Value of Immunocytologic Detection of Bone Marrow Metastases in NeuroblastomaNew England Journal of Medicine, 1991
- Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma.Journal of Clinical Pathology, 1989
- Characterization of neural cell adhesion molecules (NCAM) expressed by ewing and neuroblastoma cell linesInternational Journal of Cancer, 1987
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984